Atsuko Nakazawa, Natsuko Nakano, Akinari Fukuda, Seisuke Sakamoto, Ken‐Ichi Imadome, Toyoichiro Kudo, Kentaro Matsuoka, Mureo Kasahara – 28 November 2014 – The decision to perform liver transplantation (LT) in patients with Epstein‐Barr virus (EBV)–induced fulminant hepatic failure (FHF) relies on a precise assessment of laboratory and pathological findings. In this study, we analyzed clinical and laboratory data as well as the pathological features of the liver in order to evaluate the pathogenesis and the need for LT in 5 patients with EBV‐induced FHF.

Diego F. Calvisi – 27 November 2014

Craig McClain – 27 November 2014

Laura Gragnani, Elisa Fognani, Alessia Piluso, Barbara Boldrini, Teresa Urraro, Alessio Fabbrizzi, Cristina Stasi, Jessica Ranieri, Monica Monti, Umberto Arena, Claudio Iannacone, Giacomo Laffi, Anna Linda Zignego, for the MaSVE Study Group – 27 November 2014 – Limited data are available about the efficacy of antiviral treatment in hepatitis C virus (HCV)–associated mixed cryoglobulinemia (MC), especially concerning the long‐term effects of HCV eradication.

Dustin R. Berger, Brenton R. Ware, Matthew D. Davidson, Samuel R. Allsup, Salman R. Khetani – 25 November 2014 – Induced pluripotent stem cell‐derived human hepatocyte‐like cells (iHeps) could provide a powerful tool for studying the mechanisms underlying human liver development and disease, testing the efficacy and safety of pharmaceuticals across different patients (i.e., personalized medicine), and enabling cell‐based therapies in the clinic.

Wendy L. van der Woerd, Johanna Mulder, Franco Pagani, Ulrich Beuers, Roderick H.J. Houwen, Stan F.J. van de Graaf – 25 November 2014 – ATP8B1 deficiency is a severe autosomal recessive liver disease resulting from mutations in the ATP8B1 gene characterized by a continuous phenotypical spectrum from intermittent (benign recurrent intrahepatic cholestasis; BRIC) to progressive familial intrahepatic cholestasis (PFIC). Current therapeutic options are insufficient, and elucidating the molecular consequences of mutations could lead to personalized mutation‐specific therapies.

Yuka Inaba, Tomoko Furutani, Kumi Kimura, Hitoshi Watanabe, Sanae Haga, Yoshiaki Kido, Michihiro Matsumoto, Yasuhiko Yamamoto, Kenichi Harada, Shuichi Kaneko, Seiichi Oyadomari, Michitaka Ozaki, Masato Kasuga, Hiroshi Inoue – 25 November 2014 – The liver has robust regenerative potential in response to damage, but hepatic steatosis (HS) weakens this potential.

Naoya Yamada, Yukihiro Sanada, Yuta Hirata, Noriki Okada, Taiichi Wakiya, Yoshiyuki Ihara, Atsushi Miki, Yuji Kaneda, Hideki Sasanuma, Taizen Urahashi, Yasunaru Sakuma, Yoshikazu Yasuda, Koichi Mizuta – 25 November 2014 – In the field of pediatric living donor liver transplantation (LDLT), physicians sometimes must reduce the volume of left lateral segment (LLS) grafts to prevent large‐for‐size syndrome. There are 2 established methods for decreasing the size of an LLS graft: the use of a segment 2 (S2) monosegment graft and the use of a reduced LLS graft.

Isaac Ruiz, Cyrille Feray, Jean‐Michel Pawlotsky, Christophe Hézode – 25 November 2014

Cristiano Quintini, Mario Spaggiari, Koji Hashimoto, Federico Aucejo, Teresa Diago, Masato Fujiki, Charles Winans, Giuseppe D'Amico, Loris Trenti, Dympna Kelly, Bijan Eghtesad, Charles Miller – 25 November 2014 – The presence of portal vein thrombosis (PVT) is still considered by many transplantation centers to be an absolute contraindication to liver transplantation because of the technical difficulties that it can present and its association with a higher rate of patient morbidity and mortality. Renoportal bypass (RPB) can help to remove these barriers.